This new study has identified the fault of triple negative cancer. The discovery of the target responsible for the most virulent cancer is essential for the search for effective treatments to fight against this type of cancer, one of the most dangerous.
Researchers from the Boston University School of Medicine (BUSM) (USA) evaluated markers on the surface of breast cancer cells. They found elevated levels of a molecule, IL13R alpha2, on the surface of metastatic “triple negative” breast cancer cells.
“The treatment options are limited for ‘triple negative’ breast cancer, the discovery of alternative targets to limit its potential to progress to metastasis is urgent,” explain the authors of the study.
To validate their discovery, the scientists reduced the expression of IL13R Alpha 2 in cancer cells of genetically modified mice. They found a decrease in the tumor. By measuring this rate, researchers are able to predict the progression of the disease, and therefore adapt treatments accordingly.
“Our studies led to the unbiased discovery that IL13R alpha 2 was a major contributor in tumor progression and in the occurrence of metastases. The discovery of these cell membrane receptors that facilitate “triple negative” breast cancer metastasis will serve as a future basis for personalized therapy, ”conclude the study authors.
“Triple-negative” breast cancer, which accounts for up to 20% of cases diagnosed worldwide, strikes young women more frequently (below 40 years of age) and may be linked to genetic predispositions (in particular mutations BRCA1 or BRCA2 genes). It presents a much higher risk of the spread of metastases than other breast cancers and a much worse life-threatening prognosis.
Read also:
Breast cancer: discovery of a new gene
Breast Cancer Screening: Is It Really Helpful In Preventing The Disease?
Breast cancer: 2 generic drugs effective against recurrence